Physician profile
Mark A Rasak
NPI 1053391920
$17,087.79
in general payments reported to CMS, 2019-2025
48 companies · $3,084 in 2025
The $3,084 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,139 · 2020: $1,366 · 2021: $6,106 · 2022: $2,362 · 2023: $1,409 · 2024: $1,622 · 2025: $3,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,717 · Debt Forgiveness: $1,387 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,717.00 |
| Debt Forgiveness | $1,386.90 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $3,850.71 | 2020-2021 | |
| Lantheus Medical Imaging, INC. | $1,386.90 | 2025 | Definity |
| Novartis Pharmaceuticals Corporation | $1,266.01 | 2019-2025 | |
| Novo Nordisk INC | $1,148.16 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $1,115.76 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $1,013.61 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $806.79 | 2020-2025 | Wainua, Breztri, Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $795.56 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $736.11 | 2021-2025 | Verquvo, Steglatro, Capvaxive |
| Sanofi-Aventis U.S. LLC | $568.38 | 2019-2023 | |
| Pfizer INC. | $502.67 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $492.98 | 2020-2025 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $346.85 | 2021-2025 | Amvuttra |
| Amgen INC. | $338.58 | 2019-2024 | Repatha |
| United Therapeutics Corporation | $273.38 | 2019-2025 | Tyvaso, Tyvaso |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $224.79 | 2023 | Assure Wcd |
| Eisai INC. | $220.06 | 2019 | |
| Glaxosmithkline, LLC. | $171.46 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Actelion Pharmaceuticals US, INC. | $161.08 | 2020-2025 | Uptravi, Opsumit |
| Nestle Healthcare Nutrition INC. | $153.47 | 2021-2023 | |
| Lilly USA, LLC | $146.77 | 2021-2024 | Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $145.09 | 2021-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $139.21 | 2019-2022 | |
| Scpharmaceuticals INC. | $137.21 | 2023-2025 | |
| Lexicon Pharmaceuticals, INC. | $105.34 | 2023-2024 | Inpefa |
| Medtronic, INC. | $94.91 | 2022 | |
| Abbvie INC. | $94.72 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $68.51 | 2019-2021 | |
| Abbott Laboratories | $57.38 | 2021-2022 | |
| Dexcom, INC. | $53.48 | 2021-2023 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.36 | 2022-2024 | Caplyta |
| Edwards Lifesciences Corporation | $47.83 | 2019-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abiomed | $40.43 | 2024 | Impella |
| Regeneron Healthcare Solutions, INC. | $39.95 | 2023-2025 | Evkeeza |
| Genzyme Corporation | $35.33 | 2022 | |
| Daiichi Sankyo INC. | $32.39 | 2021-2023 | Injectafer |
| Aimmune Therapeutics, INC. | $30.06 | 2024-2025 | Zenpep |
| Boston Scientific Corporation | $24.29 | 2022 | |
| Lundbeck LLC | $23.66 | 2020 | |
| Azurity Pharmaceuticals, INC. | $21.40 | 2023 | Edarbi |
| Amryt Pharma Holdings Ltd | $17.32 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $17.23 | 2022 | |
| Arbor Pharmaceuticals, INC. | $17.20 | 2021 | |
| Bridgebio Pharma, INC. | $16.25 | 2025 | Attruby |
| Medtronic Vascular, INC. | $15.76 | 2019 | |
| Infobionic, INC | $15.23 | 2020 | |
| Vivus LLC | $13.29 | 2022 | |
| Baxter Healthcare | $12.88 | 2023 | Hillrom - Carnation Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rasak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.